JD Health Reports Robust 2026 Q3 Results: Revenue Hits 20.02 Billion Yuan with Record 50+ New Drug Launches
2 day ago / Read about 0 minute
Author:小编   

JD Health posted revenue of 20.02 billion yuan for the third quarter of 2026, alongside a Non-IFRS operating profit of 1.57 billion yuan. The company reinforced its core strengths in the pharmaceutical and healthcare supply chain, expanded full-scenario AI-powered medical applications, and further solidified its offline closed-loop model integrating "consultation, testing, diagnosis, and medication." During the quarter, JD Health achieved a record launch of over 50 new drugs—the first time it has surpassed this milestone in a single quarter—and has cumulatively partnered with more than 110 pharmaceutical companies. The total volume of new drugs launched on its platform has now exceeded that of the entire year of 2025, cementing its position as the leading platform for nationwide first launches of new drugs. Leveraging the China International Import Expo to broaden global cooperation, JD Health expanded its offerings in categories such as premium medical devices, health consumer products, and pet health, while enhancing its omnichannel fulfillment capabilities. The AI doctor "Dawei" recorded a more than fivefold year-over-year increase in average daily interactions, and the AI-powered physician workstation Medwork Zhiyi has been deployed across multiple clinical scenarios to empower healthcare professionals. On the offline front, the company broadened the reach of its testing and imaging services, opened several new comprehensive clinics, introduced the at-home nursing service "Filial Care Guardian," and recently launched its "Medical Care in China" business—altogether reflecting a steady trajectory of high-quality development.